Gilead Sciences struck a licensing deal with Genhouse Bio for GH31, a MAT2A‑targeting synthetic‑lethal oncology candidate, paying $80 million up front and agreeing up to $1.45 billion in milestones plus royalties. Genhouse has secured IND clearance in China and the U.S., positioning GH31 for rapid clinical advancement under Gilead’s oncology development engine. Gilead framed the acquisition as a targeted expansion of its oncology pipeline via high‑value partnerships; Genhouse called the transaction a major validation of its synthetic lethality platform. The deal follows Gilead’s recent string of oncology add‑ins and reflects pharma appetite for targeted DNA‑damage and metabolic vulnerabilities. The agreement accelerates GH31’s global development timeline and underscores continued cross‑border dealmaking between Chinese biotech innovation and Western strategic acquirers.